EPS for IRIDEX Corporation (IRIX) Expected At $-0.30

September 30, 2018 - By Lisa Delgado

IRIDEX Corporation (NASDAQ:IRIX) LogoInvestors sentiment increased to 0.8 in Q2 2018. Its up 0.10, from 0.7 in 2018Q1. It increased, as 2 investors sold IRIDEX Corporation shares while 8 reduced holdings. 3 funds opened positions while 5 raised stakes. 5.42 million shares or 3.03% less from 5.59 million shares in 2018Q1 were reported.
Ingalls & Snyder reported 0.01% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). 314,460 were reported by Lyon Street Cap Lc. Geode Limited Liability Company owns 37,770 shares. Finemark Commercial Bank & reported 0.02% stake. Thompson Davis Communication holds 0.01% or 500 shares in its portfolio. Smith Moore And Co reported 25,000 shares. Renaissance Technologies Ltd Liability has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). First Light Asset Limited holds 0.22% in IRIDEX Corporation (NASDAQ:IRIX) or 198,581 shares. Jacobs Levy Equity Management invested in 24,146 shares or 0% of the stock. Vanguard Gp Inc reported 0% in IRIDEX Corporation (NASDAQ:IRIX). Blair William Il has 43,600 shares. Manufacturers Life Insurance The owns 814 shares for 0% of their portfolio. Jpmorgan Chase & Communications invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Northern Trust holds 0% or 64,198 shares in its portfolio. Millennium Management Lc holds 0% or 37,538 shares.

Since September 14, 2018, it had 2 insider purchases, and 0 insider sales for $485,600 activity. On Tuesday, September 18 PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE bought $420,000 worth of IRIDEX Corporation (NASDAQ:IRIX) or 70,000 shares.

Analysts expect IRIDEX Corporation (NASDAQ:IRIX) to report $-0.30 EPS on November, 1.They anticipate $0.03 EPS change or 11.11 % from last quarter’s $-0.27 EPS. After having $-0.28 EPS previously, IRIDEX Corporation’s analysts see 7.14 % EPS growth. The stock decreased 3.05% or $0.2 during the last trading session, reaching $6.35. About 65,264 shares traded or 164.60% up from the average. IRIDEX Corporation (NASDAQ:IRIX) has declined 15.94% since September 30, 2017 and is downtrending. It has underperformed by 31.56% the S&P500.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $84.65 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

More important recent IRIDEX Corporation (NASDAQ:IRIX) news were published by: Nasdaq.com which released: “IRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiereâ„¢ Laser Accessory to the US Market” on September 06, 2018, also Globenewswire.com published article titled: “IRIDEX Announces Proposed Public Offering of Common Stock”, Seekingalpha.com published: “IRIDEX down 16% on pricing common stock offering” on September 14, 2018. More interesting news about IRIDEX Corporation (NASDAQ:IRIX) was released by: Seekingalpha.com and their article: “Iridex readies stock offering” with publication date: September 13, 2018.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: